Abstract

To investigate the effects of sertraline on T lymphocyte subsets, depression and quality of life in lung cancer patients with depression is the objective of the study. A total of 100 lung cancer patients with depression admitted from January 2020 to June 2021 were randomly divided into two groups. The control group (50 cases) received conventional clinical pathway management and psychological treatment and the research group (50 cases) received treatment on the basis of the control group and combined with sertraline 50-200 mg/d. Both groups were observed for 6 w. T lymphocyte subsets and depression was compared before and after 3, 6 w of treatment, the quality of life was compared before and after 6 w of treatment. The adverse drug reactions were also recorded. In terms of T lymphocyte subsets, the cluster of differentiation 4⁺/cluster of differentiation 8⁺ of research group was higher than control group (p<0.01). After 6 w, those in the research group were higher than control group (p<0.05) and cluster of differentiation 8⁺ was lower than control group (p<0.01). In terms of depression, the scores of self-rating depression scale and Hamilton depression scale in research group were lower than control group (p<0.05) where it decreased in both groups after 6 w (p<0.05), in which the scores in research group after 6 w were lower than those after 3 w (p<0.01). In terms of quality of life, the scores of physical function, emotional function, energy, mental health, social function and general health in the research group were higher than control group (p<0.01) and higher than those before treatment (p<0.01). In addition, there was no adverse drug reactions occurred during the period of treatment. Sertraline can improve the degree of depression, T lymphocyte subsets function and quality of life in lung cancer patients with depression and be worthy of further clinical promotion.